Selective Beta-Arrestin2 Signaling for Inflammatory Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack compounds or techniques to selectively activate the β-arrestin2-dependent signaling pathway of GPCRs, which is necessary for treating inflammatory conditions like diabetes and obesity associated with β-arrestin and GPCR-mediated responses.
Innovation Solution
Administration of therapeutically effective amounts of ω-3 fatty acids, such as DHA and EPA, which selectively activate the β-arrestin2-dependent signaling pathway of GPR120, and the use of β-arrestin2 modulating agents to treat inflammatory conditions, including diabetes and obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional GPCR ligands are used, then both G protein-dependent and β-arrestin-dependent pathways are activated equally, but this results in inability to selectively treat conditions requiring β-arrestin2-specific signaling
Solution Approach 1:
The patent applies local quality by creating ligands with differentiated binding characteristics that selectively engage β-arrestin2 over other β-arrestins or G protein pathways. The ligand structure is optimized to produce localized signaling effects specific to β-arrestin2-dependent pathways, enabling selective treatment of conditions requiring this specific signaling mechanism.
Solution Approach 2:
The patent employs parameter changes by modifying ligand molecular properties to alter signaling outcomes. Through structural modifications and optimization of binding affinity, the ligands are designed to change the signaling parameters specifically toward β-arrestin2 activation, separating this pathway from parallel G protein-dependent signaling.
2Reliability
If non-selective GPCR ligands are administered, then general inflammatory response is modulated, but specific anti-inflammatory effects mediated by β-arrestin2 are not achieved
Solution Approach 1:
The patent extracts the β-arrestin2-specific signaling function from the broader GPCR signaling umbrella. By developing ligands that selectively activate β-arrestin2, the therapy isolates and targets the specific anti-inflammatory pathway responsible for treating inflammatory conditions, separating it from other potentially harmful or less effective signaling routes.
3Productivity
If existing therapeutic compounds are used, then general inflammation is addressed, but compounds that selectively activate β-arrestin2-dependent pathways have not been provided
Solution Approach 1:
The patent performs preliminary action by systematically identifying and characterizing ligands with selective β-arrestin2 activating properties before clinical application. Through extensive screening and characterization, the invention prepares a foundation of validated selective ligands that can be directly applied to treat conditions requiring β-arrestin2-specific signaling activation.
Data Source
AI summary
The present invention provides methods of treating a β-arrestin2 mediated and/or GPR120 mediated response in a subject. The β-arrestin2 mediated and/or GPR120 mediated response can be inflammation, including diabetes, inflammation associated with obesity and obesity. The methods can comprise administering to a subject a therapeutically effective amount of a compound predicted to bind a β-arrestin2 molecule and/or GPR120, wherein the compound selectively activates a β-arrestin2-dependent signaling pathway of GPR120.